Cardinal Health, Inc. (CAH) - Q2 Fiscal 2026 Form 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2025 (Q2 Fiscal 2026). Cardinal Health is a global healthcare services and products company operating primarily through two reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD). The company also reports an "Other" segment comprising Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | Y/Y Change |
|---|---|---|---|
| Total Revenue | $65.6 billion | $55.3 billion | +19% |
| GAAP Operating Earnings | $707 million | $549 million | +29% |
| Non-GAAP Operating Earnings | $877 million | $635 million | +38% |
| GAAP Diluted EPS | $1.97 | $1.65 | +19% |
| Non-GAAP Diluted EPS | $2.63 | $1.93 | +36% |
| Net Earnings (GAAP) | $467 million | $400 million | +17% |
| Operating Cash Flow (6 Months) | $1.7 billion | ($2.0 billion) | N/A |
| Cash and Equivalents | $2.8 billion | $3.9 billion (Jun 30, 2025) | -28% |
| Total Debt Obligations | $9.0 billion | $8.5 billion (Jun 30, 2025) | +6% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 19% increase in Pharma segment revenue ($60.7 billion) due to branded and specialty pharmaceutical sales growth, including significant demand for GLP-1 products. The "Other" segment grew 34% due to at-Home Solutions and OptiFreight Logistics.
- Profitability: GAAP operating earnings rose 29% to $707 million. Non-GAAP operating earnings increased 38% to $877 million, reflecting the impact of recent Management Services Organization (MSO) acquisitions and the Advanced Diabetes Supply Group (ADS) acquisition.
- Acquisition Activity: The company completed the acquisition of Solaris Health (a urology MSO) for approximately $1.9 billion in cash on November 3, 2025. This transaction significantly impacted segment profit and goodwill.
- Interest Expense: Net interest expense increased significantly to $88 million (from $35 million in the prior year) due to additional debt financing used to fund recent acquisitions.
- Segment Performance:
- Pharma: Profit increased 29% to $687 million.
- GMPD: Profit increased to $37 million (from $18 million), aided by cost optimization but partially offset by tariff impacts.
- Other: Profit increased 52% to $179 million.
Guidance, Outlook, Risks, and Unusual Items
- Acquisition Integration: Management highlighted the positive impact of MSO platforms (The Specialty Alliance and Navista) on segment profit. Future performance depends on successful integration and retention of providers.
- GLP-1 Demand: While sales of GLP-1 pharmaceuticals increased significantly, they did not meaningfully contribute to segment profit due to supply constraints and pricing dynamics. Future demand remains unpredictable.
- Tariffs: Recent U.S. tariffs have resulted in substantial additional costs for sourcing products. The company is evaluating alternative supply sources but notes that financial results could be negatively impacted if costs cannot be offset by price increases.
- Opioid Litigation: The company has $4.3 billion accrued for opioid-related settlements. During the six months ended December 31, 2025, payments totaled $403 million. The company expects the majority of remaining payments to occur through 2038.
- Tax Contingency: The company received a Notice of Proposed Adjustment from the IRS regarding a 2017 restructuring, asserting a potential additional federal income tax liability of approximately $160 million plus interest. The company believes it has adequate reserves but notes the outcome is uncertain.
- Capital Deployment: The company deployed $758 million for share repurchases and $251 million for dividends during the first six months of fiscal 2026. A $3.5 billion share repurchase program remains active with approximately $2.0 billion remaining as of December 31, 2025.
Investor Verification Checklist
- Acquisition Accretion: Verify the long-term profitability contribution of the Solaris Health and other MSO acquisitions, specifically regarding the $500 million in share-based compensation costs associated with Solaris.
- Tariff Impact: Monitor the company's ability to pass on tariff-related cost increases to customers without losing market share, particularly in the GMPD segment.
- Opioid Cash Flow: Track the $403 million in opioid settlement payments made in the first half of the year against the $4.3 billion total accrual to ensure liquidity remains sufficient for future obligations through 2038.
- GLP-1 Margins: Assess whether the high volume of GLP-1 sales will eventually translate to improved margins or if supply constraints and pricing pressures will persist.
- IRS Audit Outcome: Review the resolution of the $160 million IRS tax assessment regarding the 2017 Patient Recovery business acquisition.
- Debt Servicing: Evaluate the impact of increased interest expense ($88 million in Q2) on future free cash flow, given the $9.0 billion total debt load.